Search

Search Results

• 

  Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients

  M. Romano, I. Pontikaki, M. Gattinara, I. Ardoino, C. Donati, P. Boracchi, P.L. Meroni, V. Gerloni

  278-285

  17-03-2014

  https://doi.org/10.4081/reumatismo.2013.682

  2944

  PDF: 1445
• 

  Drug-induced osteonecrosis of the jaw: the state of the art

  A. Fassio, F. Bertoldo, L. Idolazzi, O. Viapiana, M. Rossini, D. Gatti

  9-15

  22-05-2017

  https://doi.org/10.4081/reumatismo.2017.983

  5430

  PDF: 3015
• 

  Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study

  L. Bazzichi, D. Biasi, E. Tinazzi, M. Muratore, R. Pellerito, R. Russo, M. Corsaro Santi, P. De Sandre, O. Epis, M. Granata, B. Kroegler, C. Meschini, F. Versace, C. Astolfi

  224-232

  06-11-2014

  https://doi.org/10.4081/reumatismo.2014.748

  2557

  PDF: 1661

• PO:12:178 | Don't count your chickens before they hatch! Analysis of cardiovascular definitions in studies on rheumatic diseases: a systematic literature review Laura Pezzoni¹, Silvia Sirotti^1|2, Georgios Filippou^1|2, Piercarlo Sarzi Puttini^1|2, Greta Pellegrino^1|2. | ¹Università degli Studi di Milano, Milano; ²IRCCS Ospedale Galeazzi Sant'Ambrogio, Milano, Italy.

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2028

  136

• PO:24:063 | Interstitial lung disease in idiopathic inflammatory myopathy patients: efficacy and safety of nintedanib Giulia Buonsante^1|2|3, Giacomo De Luca^1|2|3, Veronica Batani^1|2, Lorenzo Dagna^1|2|3, Marco Matucci-Cerinic^1|2|3, Corrado Campochiaro^1|2|3 | ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases UNIRAR, IRCCS San Raffaele Hospital Milano, Italy; ²Inflammation, Fibrosis and aging Initiative INFLAGE, IRCCS San Raffaele Hospital Milano, Italy; ³Vita-Salute San Raffaele University, Milano, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2350

  23

• PO:06:081 | Safety of JAK inhibitors compared to non-TNF-targeted biologic therapies in rheumatoid arthritis patients who are inadequate responders to TNF inhibitors Lorenzo Di Luozzo¹, Alessandro Giollo¹, Mariangela Salvato¹, Francesca Frizzera¹, Kiren Khalid¹, Margherita Zen¹, Andrea Doria¹ | ¹Azienda ospedaliera universitaria di Padova, unità di Reumatologia, Padova, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2298

  29

• PO:07:108 | Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study Enrico Marchetta¹, Andrew Östör^2|8, Eugen Feist³, Prodromos Sidiropoulos⁴, Jérôme Avouac⁵, Martin Rebella^6|7, Rajaie Namas⁹, Erin Mcdearmon Blondell¹⁰, Ivan Lagunes¹⁰, Tianming Gao¹⁰, Tim Shaw¹⁰, Suzan Attar¹¹ | ¹AbbVie Srl Roma, Italy; ²Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; ³Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; ⁴Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; ⁵Service de Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; ⁶Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Montevideo, Uruguay; ⁷Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; ⁸Australian National University, Camberra, Australia; ⁹Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; ¹⁰AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; ¹¹King Abdulaziz University, Jeddah, Saudi Arabia

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2306

  16

• PO:07:096 | Safety of filgotinib in the treatment of rheumatoid arthritis: results from the multicentre SOFIA study Anna Giorgia Osele¹, Matteo Filippini², Eugenio Capparelli³, Eleonora Bruschi⁴, Bernd Raffeiner⁵, Silvano Bettio⁶, Mariangela Salvato¹, Federico Arru⁷, Massimiliano Limonta⁴, Paola Faggioli³, Elda Piovani², Eleonora Zaccara³, Alessandro Giollo¹, Margherita Zen¹ | ¹UOC Reumatologia, Azienda Ospedale-Università di Padova; ²UO Reumatologia e Immunologia Clinica, ASST Spedali Civili, Brescia; ³UOC Ruematologia, ASST Ovest Milanese, Legnano ^MI; ⁴SSD Reumatologia, ASST Papa Giovanni XXIII, Bergamo; ⁵Dipartimento di Reumatologia, Ospedale di Formazione Paracelsus ^ASDAA-SABES, Bolzano; ⁶Medicina Generale Unità 1^, Centro Regionale per le Malattie Rare Immunologiche e Reumatologiche, Ospedale Universitario Treviso; ⁷UO Medicina, ASL 3 Nuoro, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2136

  132

• PO:02:018 | After-SECs: clinical predictors of secukinumab retention in psoriatic arthritis patients with inadequate response to anti-tumor necrosis factor therapy Francesco Cristiano¹, Davide Gaspare Patti¹, Valentina Boni¹, Stefano Di Murro¹, Cesare Gavotti¹, Roberta Masnata¹, Giulia Calabrese², Gerlando Natalello², Giusy Peluso², Augusta Ortolan^1|2, Enrico De Lorenzis^1|2, Maria Antonietta D'Agostino^1|2. | ¹Università Cattolica del Sacro Cuore, Roma, Italy; ²Divisione di Reumatologia ed Immunologia clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2009

  142

• The Italian contributions to the history of salicylates

  Piero Marson, Giampiero Pasero

  66-75

  https://doi.org/10.4081/reumatismo.2006.66

  2054

  PDF: 1639